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Purpose. The purpose of this research was to determine the polarity and directionality of the PEPT2-
mediated uptake and transepithelial transport of the neuropeptide glycyl-L-glutamine (GlyGln) in
choroid plexus.
Methods. The transport kinetics of [3H]GlyGln was studied in neonatal rat choroid plexus epithelial cells
in primary culture grown on laminin-coated Transwell filter inserts. Using a bicarbonate artificial
cerebrospinal fluid (CSF) buffer (pH 7.4) at 37-C, GlyGln studies were performed as a function of time,
substrate concentration, and the presence of potential inhibitors (at 1 mM).
Results. GlyGln (2 mM) accumulation was about three to four times greater when introduced from the
apical (CSF-facing) as opposed to the basal (blood-facing) side of the cell monolayer, and transepithelial
transport was about two times greater in the apical-to-basal direction. The apical uptake of radiolabeled
GlyGln (2 mM) was inhibited significantly by dipeptides (i.e., unlabeled GlyGln and cysteinylglycine)
and some neuropeptides (i.e., carnosine, N-acetylaspartylglutamate, kyotorphin), but was unaffected by
amino acids (i.e., glycine, glutamine) as well as by [D-Arg2]-kyotorphin and glutathione. The
concentration-dependent apical uptake of GlyGln (2Y1000 mM) was characterized by a high-affinity
process (i.e., Vmax of 72 pmol/mg/min; Km of 136 mM), consistent with the properties of PEPT2. The
intracellular hydrolysis of GlyGln was extensive, however, with only 40% of the dipeptide remaining
intact after 1 h.
Conclusions. The results demonstrate that PEPT2 plays an important role in regulating the apical
uptake of GlyGln at the bloodYCSF interface. Once inside the cell, GlyGln is rapidly degraded to its
constitutive amino acids for further processing.
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INTRODUCTION
Glycyl-L-glutamine (GlyGln) is a biologically active
neuropeptide that inhibits the firing frequencies of neurons
in the nucleus reticularis gigantocellularis of rat brain stem
(1,2). It is also a potent inhibitor of the hypotension and
respiratory depression produced by intracerebroventricular
injection of morphine or b-endorphin in rats (1,2). GlyGln is
incapable of crossing the bloodYbrain barrier (3) but is,
instead, formed within the brain as a result of the proteolytic
cleavage of b-endorphin (4). Thus, GlyGln exerts its biolog-
ical activity as a metabolic fragment of polypeptide biotrans-
formation. The process by which the neuropeptide activity of
GlyGln is terminated, however, is unclear since clearance
mechanisms from the brain, including the cerebrospinal fluid
(CSF), are poorly understood for naturally occurring di- and
tripeptide substrates.
The close proximity of aminopeptidases and peptide
transporters (PEPTs) in the brain makes the coupling of pep-
tide metabolism and transport an attractive combination. In
this regard, a number of peptidases have been identified in the
choroid plexus (5). Likewise, a high-affinity proton-coupled
oligopeptide transporter, PEPT2, has been identified as being
expressed and functionally active at the apical membrane of
choroid plexus whole tissue (6Y8) epithelial cells in primary
culture (9) and native tissue (10). As a result, it is possible
that GlyGln, once formed, can be cleared by PEPT2 into the
choroid plexus, where it can then be transported into the
blood, sequestered in the tissue itself, or broken down into its
constituent amino acids for further use.
Few studies have examined the uptake and transepithelial
transport mechanisms of di- and tripeptides in the choroid
plexus. This is particularly true for biologically active pep-
tides. While the neuropeptides N-acetylaspartylglutamate
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(NAAG), cysteinylglycine (CysGly), GlyGln, kyotorphin
(KTP), and carnosine inhibited the PEPT2-mediated
uptake of radiolabeled glycylsarcosine (GlySar) in isolated
rat choroid plexus (8), the direct study of dipeptide
disposition in choroid plexus and the role of PEPT2 in this
process yielded conflicting results. In particular, the accumu-
lation and transcellular transport of GlySar (a synthetic
model dipeptide) were three to four times higher when
introduced from the apical as opposed to basal side of rat
choroid plexus epithelial cells in primary culture (9).
Likewise, carnosine (a naturally occurring neurodipeptide)
was preferentially taken up from the apical as opposed to
basolateral membrane of epithelial cell monolayers (11). In
contrast to GlySar, however, basolateral efflux was limited
and, as a result, the transepithelial flux of carnosine was not
distinguishable from that of paracellular diffusion alone.
Instead, carnosine accumulated substantially within choroid
plexus cells, achieving concentrations 135 times higher than
that of the extracellular medium.
Given the limited understanding of how neuropeptides
are handled at the bloodYCSF interface, including peptide
disposition once in the cell, the polarity and directionality of
GlyGln uptake and transport were examined in rat choroid
plexus primary cell cultures. Our results indicate that
although PEPT2 facilitates the apical uptake of GlyGln
into choroidal epithelial cells, this neuropeptide (in contrast
to GlySar and carnosine) is rapidly metabolized to its
constituent amino acids for further processing.
MATERIALS AND METHODS
All studies were carried out in accordance with the Guide
for the Care and Use of Laboratory Animals as adopted and
promulgated by the U.S. National Institutes of Health (NIH
publication No. 85-23, revised in 1985).
Materials
[3H]GlyGln (10 Ci/mmol; radiochemical purity 97.7%)
was purchased from Moravek Biochemicals (Brea, CA) and
[14C]mannitol (53 mCi/mmol) from American Radiolabeled
Chemicals (St. Louis, MO). Unlabeled glycine and glutamine
(i.e., amino acids), CysGly (i.e., dipeptide precursor of
glutathione), and GlyGln, carnosine, NAAG, KTP, [D-
Arg2]kyotorphin (DKTP) and glutathione (GSH) (i.e.,
neuropeptides) were purchased from Sigma (St. Louis,
MO). Other chemicals were obtained from standard sources
and were of the highest quality available.
Intracellular Accumulation and Transepithelial
Transport of GlyGln in Cell Cultures
Choroid plexus epithelial cells in primary culture were
obtained from the lateral ventricles of 1- to 2-day-old
Sprague-Dawley rats using the method of Strazielle and
Ghersi-Egea (12). This method was validated and applied
previously by our group in studying the uptake and transport
kinetics of GlySar (9) and carnosine (11) at the bloodYCSF
barrier. In brief, choroid plexus cells were collected and
seeded on laminin-coated Transwell-Clear filter inserts (12
mm diameter, 0.4 mm pore size; Costar Plastics, Cambridge,
MA). The culture medium was changed every 48 h after
seeding and consisted of Dulbecco’s minimum essential
medium (DMEM)/F-12 (1:1) supplemented with 10% (v/v)
fetal bovine serum, 2 mM glutamine, 25 mg/ml of gentamicin,
5 mg/ml of insulin, 5 mg/ml of transferrin, 5 ng/ml of sodium
selenite, 10 ng/ml of epidermal growth factor, 2 mg/ml of
hydrocortisone, and 5 ng/ml of basic fibroblast growth factor.
Cells were grown in a sterile incubator at 37-C, 95% relative
humidity, and 5% CO2. Cultures were inspected visually for
epithelial growth (i.e., cobblestone appearance) on a regular
basis, and confluence occurred 5Y7 days post-seeding. Trans-
epithelial electrical resistance measurements were performed
prior to experimentation (using a Millicell-ERS; Millipore
Corp., Bedford, MA) as a measure of monolayer integrity.
Values of Q150 ohm I cm2 were reached at 10Y14 days post-
seeding, and were considered sufficient for experimentation.
Uptake and transport studies were performed in a
bicarbonate artificial CSF buffer that consisted of (in
mM): 127 NaCl, 20 NaHCO3, 2.4 KCl, 0.5 KH2PO4, 1.1
CaCl2, 0.85 MgCl2, 0.5 Na2SO4, and 5.0 glucose (pH 7.4),
bubbled with 5% CO2 and 95% O2. Cell monolayers were
preincubated apically (0.4 ml) and basolaterally (1.2 ml) with
this buffer at 37-C for 10 min. The buffer was removed and
fresh buffer containing [3H]GlyGln and [14C]mannitol, with
and without inhibitors, was added to the apical side (0.4 ml)
or basolateral side (1.2 ml); control buffer (no isotope) was
added to the opposite side. The cells were then incubated for
the indicated period of time at 37-C. To measure
transepithelial transport, an aliquot (100 ml) of the buffer
was taken from the opposite side and the radioactivity was
counted. To measure intracellular accumulation, the media
were aspirated at the end of the incubation period and the
monolayers rapidly washed four times on both sides with ice-
cold buffer. The filters with monolayers were detached from
the chambers and cells were solubilized in 0.5 ml of 0.2 M
NaOH and 1% sodium dodecyl sulfate (SDS). The
radioactivity of the collected buffer and of the solubilized
cells was determined by liquid scintillation counting. The
protein content of the solubilized cell monolayers was
determined using a protein assay kit (Bio-Rad Laboratories,
Hercules, CA) with bovine serum albumin as the standard.
GlyGln uptake data were corrected for filter binding and
extracellular content, as described previously (7). The trans-
epithelial transport of GlyGln was corrected for paracellular
flux, as estimated by mannitol (9).
Stability of GlyGln
The stability of GlyGln was evaluated in the apical,
basolateral, and intracellular compartments of choroid plexus
epithelial cells. Following the preparation of cell monolayers,
as described previously, 2 mM of [3H]GlyGln was incubated
in the apical chamber for 5, 15, 30, and 60 min at 37-C. At the
end of incubation, media from the apical and basolateral
compartments were aspirated and saved for analysis. Cell
monolayers were washed four times with ice-cold buffer, the
filters detached, and 0.5 ml of ice-cold Milli-Q water
(Millipore Corp.) added prior to sonication for 10 min. Cell
lysates were then treated with an equal volume of aceto-
nitrile, vortex-mixed for 5 s, and centrifuged at 12,000 rpm
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for 5 min at 4-C. The supernates were concentrated under
cryo-vacuum (SpeedVac refrigerated concentrator; Savant
Instruments Inc., Farmingdale, NY) and analyzed by high-
performance liquid chromatography (HPLC). The stability of
GlyGln was also evaluated in lysates prepared from choroid
plexus whole tissue. For these preparations, 14Y16 choroid
plexuses were pooled from 7Y8 neonatal rats and sonicated
(1-s burst  3) in ice-cold artificial CSF buffer. Tissue lysate
(7.2 mg protein per 180 ml of buffer) was preincubated for
5 min at 37-C and [3H]GlyGln added to the mixture. GlyGln
was then incubated continuously in tissue lysate (at pH 7.4
and pH 5.0) and samples (25 ml) were obtained at 2, 5, 15, 30,
and 60 min at 37-C. Samples were then centrifuged at 12,000
rpm for 5 min at 4-C and analyzed by HPLC. GlyGln stability
was determined by its recovery and by the appearance of
glycine and glutamine following incubation.
Glycine, glutamine, and GlyGln were detected using an
HPLC system consisting of a pump (Waters, Model 510,
Milford, MA), a reversed-phase column (Hypersil ODS,
C-18, 5 mm, 250 mm  4.6 mm, Alltech, Deerfield, IL) and
a radiochromatography detector (FLO-ONE 500TR, Pack-
ard Instrument Co., Meriden, CT). The mobile phase was
comprised of 0.01 M phosphate buffer (pH 2.0) and 0.1%
heptafluorobutyric acid, and pumped isocratically at 1 ml /min.
Retention times for glycine, glutamine, and GlyGln were
4.07, 4.23, and 9.30 min, respectively, under ambient con-
ditions. Peaks were identified by injecting known standards
of radiolabeled glycine, glutamine, and GlyGln (Moravek
Biochemicals).
Data Analysis
For kinetic studies, the concentration-dependent uptake
of GlyGln was best fit to a Michaelis-Menten relationship
such that: V = Vmax I S/(Km + S), where Vmax is the maximal
rate of saturable uptake, Km is the Michaelis constant, and S
is the substrate concentration. To evaluate if more than one
class of transporters was operational for GlyGln uptake, a
Woolf-Augustinsson-Hofstee transformation was performed
on the saturable component where: V = Vmax Y Km(V/S).
Data are reported as means T SE (unless otherwise
indicated), with data from each experiment determined in
duplicate or triplicate. Statistical comparisons were per-
formed with ANOVA (GraphPad Prism, v3.0; GraphPad
Software, Inc., San Diego, CA) and post hoc pairwise
comparisons made with Dunnett’s test. A probability of p e
0.05 was considered statistically significant. Linear and
nonlinear regression analyses were performed with Sigma-
Plot 8.0 (SPSS Inc., Chicago, IL) and a weighting factor of
unity. The quality of fit was determined by evaluating the
coefficient of determination (r2), the coefficient of variation
(CV%) of parameter estimates, and by visual inspection of
the residuals.
RESULTS AND DISCUSSION
Time Course of GlyGln Accumulation
and Transepithelial Transport
As shown in Fig. 1, the uptake of GlyGln was sub-
stantially greater when introduced from the apical than from
the basolateral surface of the cell monolayers (i.e., about
three to four times). Similarly, the apical-to-basolateral flux
of GlyGln was greater than that of GlyGln in the reverse
direction (i.e., about two times) (Fig. 2). Given the strong
preference of GlyGln for apical uptake, along with PEPT2
being localized to the apical surface of choroid plexus
epithelial cells, the kinetic properties (Vmax, Km) and speci-
ficity (T potential inhibitors) of GlyGln were further charac-
terized at this membrane surface alone. For these analyses,
initial rates were determined at 2 min, a time in which GlySar
was still in the linear region of uptake.
Fig. 1. Intracellular accumulation of GlyGln as a function of time in
choroid plexus epithelial cells. Studies were performed with 2 2M
each of [3H]GlyGln (0.04 2Ci) and [14C]mannitol (0.02 2Ci; a marker
for extracellular content) in bicarbonate artificial CSF buffer (pH
7.4) at 37-C. Data are expressed as means T SE (n = 8). The apical
uptake of GlyGln was significantly greater than basolateral uptake at
all times, except at 0.5 and 1.0 min.
Fig. 2. Transepithelial transport of GlyGln as a function of time in
choroid plexus epithelial cells. Studies were performed with 2 2M
each of [3H]GlyGln (0.04 mCi) and [14C]mannitol (0.02 2Ci; a marker
for paracellular transport) in bicarbonate artificial CSF buffer (pH
7.4) at 37-C. Data are expressed as means T SE (n = 16). The apical-
to-basolateral transport of GlyGln was significantly greater than
basolateral-to-apical transport at all times, except at 2.0 min.
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Concentration-Dependent Apical Uptake of GlyGln
The apical uptake of GlyGln was probed over a buffer
concentration range of 2Y1000 mM. As shown in Fig. 3,
GlyGln was taken up by choroid plexus epithelial cells in a
concentration-dependent manner with a Vmax of 72.5 T 2.7
pmol/mg/min and a Km of 137 T 18 mM (r
2 = 0.991). Only
one transport system was involved in the apical uptake
of GlyGln, as suggested by the single linear slope during
a Woolf-Augustinsson-Hofstee transformation of the data
(see insert, r2 = 0.926). These values are consistent with that
of PEPT2 in choroid plexus whole tissue (i.e., high-affinity
interactions with Km values of 39Y260 mM for peptides /
mimetics) (5) and, in particular, with that of GlySar (i.e.,
Vmax of 31 pmol/mg/min, Km of 60 mM) (9) and carnosine
(i.e., Vmax of 73 pmol/mg/min, Km of 34 mM) (11) in choroid
plexus primary cell cultures.
Specificity of Apical Uptake for GlyGln
The specificity of GlyGln’s apical uptake was probed
using a wide range of potential amino acid, dipeptide, and
neuropeptide inhibitors (Fig. 4). The constitutive amino acids
of GlyGln were without effect, confirming the stability of
GlyGln during the incubation process. As expected, GlyGlnFig. 3. Concentration-dependent uptake of GlyGln in choroid plexus
epithelial cells. The 2-min apical uptake of [3H]GlyGln (0.04Y1.2 2Ci;
2Y1000 2M total drug) was evaluated in bicarbonate artificial CSF
buffer (pH 7.4) at 37-C; [14C]mannitol (0.02Y0.4 2Ci; 2 2M total
compound) was also present as a marker for extracellular content.
The experimental data are expressed as means T SE (n = 4Y8). The
predicted curve was generated using the mean parameters for Vmax
and Km, as determined by nonlinear regression (r
2 = 0.991) and
reported in the text. The inset is a WoolfYAugustinssonYHofstee plot
of the transformed data [uptake (V), pmol/mg/min vs. uptake per
concentration (V/[S], 2l/mg/min], which is linear (r2 = 0.926). Error
bars are omitted in the inset for clarity.
Fig. 4. Effect of potential inhibitors on the apical uptake of GlyGln
in choroid plexus epithelial cells. The 2-min apical uptake of 2 2M
[3H]GlyGln (0.04 2Ci) was evaluated in bicarbonate artificial CSF
buffer (pH 7.4) at 37-C; 2 2M [14C]mannitol (0.02 2Ci) was also
present as a marker for extracellular content. The experimental data
are expressed as mean T SE (n = 4Y9). **p < 0.01 as compared to
control values.
Fig. 5. (A) GlyGln stability as a function of time in choroid plexus
epithelial cells. Studies were performed in bicarbonate artificial CSF
buffer (pH 7.4) at 37-C in which monolayers were incubated apically
with 2 2M of [3H]GlyGln. Stability was assessed in the apical and
basolateral chambers, and in the intracellular compartment. Data are
expressed as the mean of two experiments (e10% difference between
studies). (B) GlyGln stability as a function of time in choroid plexus
whole tissue lysates (pH 7.4 and pH 5.0). Data are expressed as the
means of two preparations (with each preparation containing 14Y16
choroid plexuses from 7Y8 animals). Control studies were also
performed in buffer alone (pH 7.4 and pH 5.0).
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exhibited self-inhibition (i.e., reduced accumulation of radio-
label in the presence of unlabeled dipeptide) along with
inhibition by the dipeptide CysGly (about 80Y85%). With
respect to neuropeptides, GlyGln was inhibited by carnosine
(74%), NAAG (38%), and KTP (81%), but was not inhib-
ited by DKTP or GSH. Thus, it appears that the apical up-
take of GlyGln into choroid plexus cells may be influenced
by dipeptide fragments and/or neuropeptides that share
the same pharmacophore for PEPT2. For example, DKTP
(L-Tyr-D-Arg) is a stereoisomer of KTP (L-Tyr-L-Arg) in
which the L-configuration is preferred for transport. Like-
wise, free amino acids that are one (i.e., a-position) or at
most two (i.e., b-position) methylene groups from the
backbone carbonyl group have been demonstrated to exhibit
a high-affinity transport by PEPT2 (13). GSH, with a free
amino acid in the g-position would, therefore, have a much
reduced or nonexistent uptake.
Stability of GlyGln
For those primary cell culture studies in which 2-min
uptakes were determined (i.e., kinetic and inhibition experi-
ments), GlyGln was found to be stable during the incubation
period. As shown in Fig. 5A, 99.8% and 96.2% of the label
remained intact in the apical and basolateral compartments,
respectively, at 60 min. In contrast, the intracellular com-
partment retained 97.9% of the intact label at 5 min, 90.6%
at 15 min, 74.7% at 30 min, and only 40.6% after 60 min of
incubation. Given the substantial metabolism of GlyGln at 60
min, yet the insignificant amount of degradation product
found in apical or basolateral chambers, it appears that the
constituent amino acids remain in the cell for further
processing. To further understand the intracellular degrada-
tion of GlyGln, additional experiments were performed in
lysates prepared from choroid plexus whole tissue. As shown
in Fig. 5B, only about 15% of the drug was metabolized in
pH 7.4 tissue lysate after 60 min of incubation, whereas about
43% of GlyGln was metabolized in pH 5.0 tissue lysate over
the same time period. In contrast, control experiments
(GlyGln added to buffer) showed no degradation of GlyGln
as a function of pH alone. These results suggest that GlyGln
may be preferentially metabolized in lysosomes, where a pH
of about 5.0 in its interior is optimal for the activity of
hydrolytic enzymes (14).
PEPT2 is a member of the proton-coupled oligopeptide
transporter family along with PEPT1 and the peptide/his-
tidine transporters (PHTs) PHT1 and PHT2 (15Y18). Immu-
nolocalization studies (9,10) have confirmed that whereas
PEPT2 protein is expressed widely throughout the brain,
including the apical membrane of choroid plexus, PEPT1
protein is absent in this tissue. Functional studies, using
inhibition of radiolabeled dipeptide by excess L-histidine,
have consistently failed to support a role for the peptide/
histidine transporters, PHT1 and PHT2, at the plasma mem-
brane of choroid plexus tissue (6Y8) and primary cell cultures
(9,11). Moreover, studies in wild type and PEPT2 null mice
have clearly demonstrated that PEPT2 is responsible for
about 80Y95% of the uptake of GlySar (19,20), 5-aminolevu-
linic acid (20), carnosine (11), and cefadroxil (21) in choroid
plexus whole tissue. Despite our current understanding that
PEPT2 plays a predominant role in the choroid plexus uptake
of peptides/mimetics and peptide-like drugs, the disposi-
tion of specific neuropeptides, as opposed to model synthetic
dipeptide probes, at the bloodYCSF barrier (BCSFB) is still
uncertain.
In the present study, we studied the uptake, trans-
epithelial transport, and cellular metabolism of GlyGln, a
dipeptide fragment of b-endorphin proteolysis, in choroid
plexus epithelial cells in primary culture. We found that
GlyGln is preferentially taken up and transported across
choroid plexus epithelium by a PEPT2-mediated process
at the apical surface of the cell membrane. We also
found that GlyGln is rapidly degraded intracellularly,
probably by lysosomes, into its constitutive amino acids.
The ability to provide free glycine and glutamine for
utilization by the cellular machinery might have signifi-
cant value. In this context, glycine could combine with
GluCys to form the antioxidant glutathione (22), and
glutamine could be used in protein synthesis, as a nitrogen
donor for the synthesis of purines, pyrimidines, nucleotides,
and amino sugars, and in the regulation of acidYbase balance
(23). The importance of GlyGln as a source of free amino
acids for these potential functions needs to be determined,
however. Taken as a whole, PEPT2 serves as a conduit for a
wide range of di- and tripeptides, neuropeptides, and
peptide-like drugs to access the choroid plexus cell from the
CSF. The disposition of these substrates, however, may vary
once in the cell. While some peptides may be effluxed into
the blood, as found for the hydrolysis- and peptidase-resistant
dipeptide GlySar (9), others may accumulate in the choroid
plexus, as observed for carnosine (11). In contrast, GlyGln is
metabolized intracellularly by the choroid plexus, where it
can then be recycled.
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